BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

683 related articles for article (PubMed ID: 27639803)

  • 1. Cell Culture System for Analysis of Genetic Heterogeneity Within Hepatocellular Carcinomas and Response to Pharmacologic Agents.
    Gao Q; Wang ZC; Duan M; Lin YH; Zhou XY; Worthley DL; Wang XY; Niu G; Xia Y; Deng M; Liu LZ; Shi JY; Yang LX; Zhang S; Ding ZB; Zhou J; Liang CM; Cao Y; Xiong L; Xi R; Shi YY; Fan J
    Gastroenterology; 2017 Jan; 152(1):232-242.e4. PubMed ID: 27639803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomic and Epigenomic Features of Primary and Recurrent Hepatocellular Carcinomas.
    Ding X; He M; Chan AWH; Song QX; Sze SC; Chen H; Man MKH; Man K; Chan SL; Lai PBS; Wang X; Wong N
    Gastroenterology; 2019 Dec; 157(6):1630-1645.e6. PubMed ID: 31560893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Variable Intra-Tumor Genomic Heterogeneity of Multiple Lesions in Patients With Hepatocellular Carcinoma.
    Xue R; Li R; Guo H; Guo L; Su Z; Ni X; Qi L; Zhang T; Li Q; Zhang Z; Xie XS; Bai F; Zhang N
    Gastroenterology; 2016 Apr; 150(4):998-1008. PubMed ID: 26752112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Analysis of Liver Cancer Cell Lines Identifies Agents With Likely Efficacy Against Hepatocellular Carcinoma and Markers of Response.
    Caruso S; Calatayud AL; Pilet J; La Bella T; Rekik S; Imbeaud S; Letouzé E; Meunier L; Bayard Q; Rohr-Udilova N; Péneau C; Grasl-Kraupp B; de Koning L; Ouine B; Bioulac-Sage P; Couchy G; Calderaro J; Nault JC; Zucman-Rossi J; Rebouissou S
    Gastroenterology; 2019 Sep; 157(3):760-776. PubMed ID: 31063779
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inferring the progression of multifocal liver cancer from spatial and temporal genomic heterogeneity.
    Shi JY; Xing Q; Duan M; Wang ZC; Yang LX; Zhao YJ; Wang XY; Liu Y; Deng M; Ding ZB; Ke AW; Zhou J; Fan J; Cao Y; Wang J; Xi R; Gao Q
    Oncotarget; 2016 Jan; 7(3):2867-77. PubMed ID: 26672766
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clonal heterogeneity influences drug responsiveness in renal cancer assessed by ex vivo drug testing of multiple patient-derived cancer cells.
    Saeed K; Ojamies P; Pellinen T; Eldfors S; Turkki R; Lundin J; Järvinen P; Nisen H; Taari K; Af Hällström TM; Rannikko A; Mirtti T; Kallioniemi O; Östling P
    Int J Cancer; 2019 Mar; 144(6):1356-1366. PubMed ID: 30125350
    [TBL] [Abstract][Full Text] [Related]  

  • 7. H3B-6527 Is a Potent and Selective Inhibitor of FGFR4 in FGF19-Driven Hepatocellular Carcinoma.
    Joshi JJ; Coffey H; Corcoran E; Tsai J; Huang CL; Ichikawa K; Prajapati S; Hao MH; Bailey S; Wu J; Rimkunas V; Karr C; Subramanian V; Kumar P; MacKenzie C; Hurley R; Satoh T; Yu K; Park E; Rioux N; Kim A; Lai WG; Yu L; Zhu P; Buonamici S; Larsen N; Fekkes P; Wang J; Warmuth M; Reynolds DJ; Smith PG; Selvaraj A
    Cancer Res; 2017 Dec; 77(24):6999-7013. PubMed ID: 29247039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor-Associated Neutrophils Recruit Macrophages and T-Regulatory Cells to Promote Progression of Hepatocellular Carcinoma and Resistance to Sorafenib.
    Zhou SL; Zhou ZJ; Hu ZQ; Huang XW; Wang Z; Chen EB; Fan J; Cao Y; Dai Z; Zhou J
    Gastroenterology; 2016 Jun; 150(7):1646-1658.e17. PubMed ID: 26924089
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circumventing intratumoral heterogeneity to identify potential therapeutic targets in hepatocellular carcinoma.
    Huang A; Zhao X; Yang XR; Li FQ; Zhou XL; Wu K; Zhang X; Sun QM; Cao Y; Zhu HM; Wang XD; Yang HM; Wang J; Tang ZY; Hou Y; Fan J; Zhou J
    J Hepatol; 2017 Aug; 67(2):293-301. PubMed ID: 28323123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Single-Cell DNA Sequencing Reveals Punctuated and Gradual Clonal Evolution in Hepatocellular Carcinoma.
    Guo L; Yi X; Chen L; Zhang T; Guo H; Chen Z; Cheng J; Cao Q; Liu H; Hou C; Qi L; Zhu Z; Liu Y; Kong R; Zhang C; Zhou X; Zhang Z; Song T; Xue R; Zhang N
    Gastroenterology; 2022 Jan; 162(1):238-252. PubMed ID: 34481846
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genomic portrait of resectable hepatocellular carcinomas: implications of RB1 and FGF19 aberrations for patient stratification.
    Ahn SM; Jang SJ; Shim JH; Kim D; Hong SM; Sung CO; Baek D; Haq F; Ansari AA; Lee SY; Chun SM; Choi S; Choi HJ; Kim J; Kim S; Hwang S; Lee YJ; Lee JE; Jung WR; Jang HY; Yang E; Sung WK; Lee NP; Mao M; Lee C; Zucman-Rossi J; Yu E; Lee HC; Kong G
    Hepatology; 2014 Dec; 60(6):1972-82. PubMed ID: 24798001
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma.
    Xu LX; He MH; Dai ZH; Yu J; Wang JG; Li XC; Jiang BB; Ke ZF; Su TH; Peng ZW; Guo Y; Chen ZB; Chen SL; Peng S; Kuang M
    Ann Oncol; 2019 Jun; 30(6):990-997. PubMed ID: 30916311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets.
    Schulze K; Imbeaud S; Letouzé E; Alexandrov LB; Calderaro J; Rebouissou S; Couchy G; Meiller C; Shinde J; Soysouvanh F; Calatayud AL; Pinyol R; Pelletier L; Balabaud C; Laurent A; Blanc JF; Mazzaferro V; Calvo F; Villanueva A; Nault JC; Bioulac-Sage P; Stratton MR; Llovet JM; Zucman-Rossi J
    Nat Genet; 2015 May; 47(5):505-511. PubMed ID: 25822088
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diverse modes of clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell genome sequencing.
    Duan M; Hao J; Cui S; Worthley DL; Zhang S; Wang Z; Shi J; Liu L; Wang X; Ke A; Cao Y; Xi R; Zhang X; Zhou J; Fan J; Li C; Gao Q
    Cell Res; 2018 Mar; 28(3):359-373. PubMed ID: 29327728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trunk mutational events present minimal intra- and inter-tumoral heterogeneity in hepatocellular carcinoma.
    Torrecilla S; Sia D; Harrington AN; Zhang Z; Cabellos L; Cornella H; Moeini A; Camprecios G; Leow WQ; Fiel MI; Hao K; Bassaganyas L; Mahajan M; Thung SN; Villanueva A; Florman S; Schwartz ME; Llovet JM
    J Hepatol; 2017 Dec; 67(6):1222-1231. PubMed ID: 28843658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient-derived multicellular tumor spheroids towards optimized treatment for patients with hepatocellular carcinoma.
    Song Y; Kim JS; Kim SH; Park YK; Yu E; Kim KH; Seo EJ; Oh HB; Lee HC; Kim KM; Seo HR
    J Exp Clin Cancer Res; 2018 May; 37(1):109. PubMed ID: 29801504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.
    Ng CKY; Bidard FC; Piscuoglio S; Geyer FC; Lim RS; de Bruijn I; Shen R; Pareja F; Berman SH; Wang L; Pierga JY; Vincent-Salomon A; Viale A; Norton L; Sigal B; Weigelt B; Cottu P; Reis-Filho JS
    Clin Cancer Res; 2017 Aug; 23(15):4402-4415. PubMed ID: 28351929
    [No Abstract]   [Full Text] [Related]  

  • 18. Multiregional whole-genome sequencing of hepatocellular carcinoma with nodule-in-nodule appearance reveals stepwise cancer evolution.
    Takeda H; Takai A; Kumagai K; Iguchi E; Arasawa S; Eso Y; Shimizu T; Ueda Y; Taura K; Uemoto S; Kita R; Haga H; Marusawa H; Fujimoto A; Seno H
    J Pathol; 2020 Dec; 252(4):398-410. PubMed ID: 32815153
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetic Features of Aflatoxin-Associated Hepatocellular Carcinoma.
    Zhang W; He H; Zang M; Wu Q; Zhao H; Lu LL; Ma P; Zheng H; Wang N; Zhang Y; He S; Chen X; Wu Z; Wang X; Cai J; Liu Z; Sun Z; Zeng YX; Qu C; Jiao Y
    Gastroenterology; 2017 Jul; 153(1):249-262.e2. PubMed ID: 28363643
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased FGF19 copy number is frequently detected in hepatocellular carcinoma with a complete response after sorafenib treatment.
    Kaibori M; Sakai K; Ishizaki M; Matsushima H; De Velasco MA; Matsui K; Iida H; Kitade H; Kwon AH; Nagano H; Wada H; Haji S; Tsukamoto T; Kanazawa A; Takeda Y; Takemura S; Kubo S; Nishio K
    Oncotarget; 2016 Aug; 7(31):49091-49098. PubMed ID: 27384874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 35.